Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma

PR-104 is a clinical stage bioreductive prodrug that is converted in vivo to its cognate alcohol, PR-104A. This dinitrobenzamide mustard is reduced to activated DNA cross-linking metabolites (hydroxylamine PR-104H and amine PR-104M) under hypoxia by one-electron reductases and independently of hypox...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Biol Ther
Autors principals: Abbattista, Maria R, Jamieson, Stephen M F, Gu, Yongchuan, Nickel, Jennifer E, Pullen, Susan M, Patterson, Adam V, Wilson, William R, Guise, Christopher P
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2015
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4622463/
https://ncbi.nlm.nih.gov/pubmed/25869917
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2015.1017171
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars